Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
Provided By PR Newswire
Last update: May 8, 2025
- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) -
Read more at prnewswire.com
